Clinical Trial Update: Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating memantine hydrochloride with whole-brain radiotherapy (with or without hippocampal avoidance) to reduce neurocognitive decline in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Cognitive Impairment

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: NRG Oncology | Conditions: Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain | Phase 3 | Status: COMPLETED | Results posted: 2020-03-06